Published in J Neurosci Res on September 01, 2008
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet (2009) 2.69
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem (2010) 2.21
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J (2013) 1.31
The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener (2009) 1.23
Tau in physiology and pathology. Nat Rev Neurosci (2015) 1.15
Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell (2014) 1.11
Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J (2012) 1.07
Hsc70 rapidly engages tau after microtubule destabilization. J Biol Chem (2010) 1.06
Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry (2011) 1.05
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med (2009) 0.99
Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem (2012) 0.99
Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol (2012) 0.94
Protein homeostasis, aging and Alzheimer's disease. Mol Neurobiol (2012) 0.93
Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem (2011) 0.92
DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau. J Mol Biol (2012) 0.92
Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep (2015) 0.91
Molecular chaperones and neuronal proteostasis. Semin Cell Dev Biol (2015) 0.91
Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry (2012) 0.87
Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. Biomed Res Int (2014) 0.87
Microtubule-associated protein tau in human prostate cancer cells: isoforms, phosphorylation, and interactions. J Cell Biochem (2009) 0.83
Vulnerabilities in the tau network and the role of ultrasensitive points in tau pathophysiology. PLoS Comput Biol (2010) 0.82
Isoform-selective Genetic Inhibition of Constitutive Cytosolic Hsp70 Activity Promotes Client Tau Degradation Using an Altered Co-chaperone Complement. J Biol Chem (2015) 0.82
DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. EMBO J (2016) 0.81
Exploiting the diversity of the heat-shock protein family for primary and secondary tauopathy therapeutics. Curr Neuropharmacol (2011) 0.81
The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Hum Mol Genet (2015) 0.80
Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. PLoS One (2014) 0.80
Cellular factors modulating the mechanism of tau protein aggregation. Cell Mol Life Sci (2015) 0.79
Molecular Chaperone Accumulation in Cancer and Decrease in Alzheimer's Disease: The Potential Roles of HSF1. Front Neurosci (2017) 0.75
Therapeutic Strategies for Restoring Tau Homeostasis. Cold Spring Harb Perspect Med (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47
Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell (1993) 15.70
Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci (2005) 9.75
Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science (1990) 5.88
Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature (1994) 4.75
A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science (1989) 4.58
Substrate specificity of the DnaK chaperone determined by screening cellulose-bound peptide libraries. EMBO J (1997) 4.28
Radioimmunoassay for tubulin: a quantitative comparison of the tubulin content of different established tissue culture cells and tissues. Cell (1978) 3.79
An enzyme that removes clathrin coats: purification of an uncoating ATPase. J Cell Biol (1984) 3.77
Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A (2000) 3.49
Domains of tau protein and interactions with microtubules. Biochemistry (1994) 3.23
Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J Cell Biol (1985) 3.16
Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol (1991) 2.85
Generation of deletion and point mutations with one primer in a single cloning step. Biotechniques (2000) 2.81
Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol (1994) 2.61
The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J Biol Chem (1996) 2.41
Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem (2001) 2.32
Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A (2003) 2.32
The ATPase core of a clathrin uncoating protein. J Biol Chem (1987) 2.28
CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem (2003) 2.27
Mutations causing neurodegenerative tauopathies. Biochim Biophys Acta (2005) 2.24
Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem (1997) 2.14
Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci (1998) 2.11
Common and divergent peptide binding specificities of hsp70 molecular chaperones. J Biol Chem (1994) 2.11
In vivo newly translated polypeptides are sequestered in a protected folding environment. EMBO J (1999) 2.08
Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci (2004) 1.88
Dominant-interfering Hsc70 mutants disrupt multiple stages of the clathrin-coated vesicle cycle in vivo. J Cell Biol (2001) 1.81
Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem (2006) 1.77
HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J (2006) 1.75
Characterization of rapidly degraded polypeptides in mammalian cells reveals a novel layer of nascent protein quality control. J Biol Chem (2005) 1.62
Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease. J Biol Chem (2000) 1.59
Sites of tau important for aggregation populate {beta}-structure and bind to microtubules and polyanions. J Biol Chem (2005) 1.54
Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem (2005) 1.45
Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem (2004) 1.42
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry (2006) 1.39
Identification of the peptide binding domain of hsc70. 18-Kilodalton fragment located immediately after ATPase domain is sufficient for high affinity binding. J Biol Chem (1993) 1.36
Functional interaction of the auxilin J domain with the nucleotide- and substrate-binding modules of Hsc70. J Biol Chem (1997) 1.35
Functional organization of microtubule-associated protein tau. Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro. J Biol Chem (1993) 1.33
Hsc70-binding peptides selected from a phage display peptide library that resemble organellar targeting sequences. J Biol Chem (1995) 1.27
Two separate 18-amino acid domains of tau promote the polymerization of tubulin. J Biol Chem (1989) 1.19
Tissue-specific differences in heat shock protein hsc70 and hsp70 in the control and hyperthermic rabbit. J Cell Physiol (1997) 1.12
BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of Tau protein. J Biol Chem (2007) 1.10
Constitutive expression of heat shock proteins Hsp90, Hsc70, Hsp70 and Hsp60 in neural and non-neural tissues of the rat during postnatal development. Cell Stress Chaperones (1998) 1.05
Human tau becomes phosphorylated and forms filamentous deposits when overexpressed in lamprey central neurons in situ. Proc Natl Acad Sci U S A (1997) 1.05
Nucleotide sequence of the cDNA of a bovine 70 kilodalton heat shock cognate protein. Nucleic Acids Res (1990) 1.01
Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain. J Neurosci Res (2007) 1.00
A mutational study of the peptide-binding domain of Hsc70 guided by secondary structure prediction. J Biol Chem (1997) 0.99
TMAO promotes fibrillization and microtubule assembly activity in the C-terminal repeat region of tau. Biochemistry (2006) 0.98
Complex formation between clathrin and uncoating ATPase. J Biol Chem (1994) 0.97
Interaction of DnaK with native proteins and membrane proteins correlates with their accessible hydrophobicity. Gene (1999) 0.94
Fibers of tau fragments, but not full length tau, exhibit a cross beta-structure: implications for the formation of paired helical filaments. Protein Sci (2000) 0.92
Involvement of the 10-kDa C-terminal fragment of hsc70 in complexing with unfolded protein. Arch Biochem Biophys (1996) 0.91
Identification of proteins binding the native tubulin dimer. Biochem Biophys Res Commun (2005) 0.88
Heat shock proteins protect against stress-related phosphorylation of tau in neuronal PC12 cells that have acquired thermotolerance. J Neurosci (1994) 0.88
Heat shock transcription factors and the hsp70 induction response in brain and kidney of the hyperthermic rat during postnatal development. J Neurochem (2000) 0.85
Stress proteins in Alzheimer's disease. Int J Hyperthermia (2005) 0.85
Heat-shock cognate 70 is required for the activation of heat-shock factor 1 in mammalian cells. Biochem J (2005) 0.84
The dynamic instability of microtubules is required for aggresome formation in oligodendroglial cells after proteolytic stress. J Mol Neurosci (2006) 0.83
Binding of heat-shock protein 70 (hsp70) to tubulin. Arch Biochem Biophys (1994) 0.83
Tau-inclusion body formation in oligodendroglia: the role of stress proteins and proteasome inhibition. Int J Dev Neurosci (2004) 0.82
The role of tau phosphorylation in transfected COS-1 cells. Mol Cell Biochem (1995) 0.81
In vitro tau fibrillization: mapping protein regions. Biochim Biophys Acta (2006) 0.78
Reversible phosphorylation of tau to form A68 in heat-shocked neuronal PC12 cells. Brain Res Mol Brain Res (1993) 0.77
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A (2003) 3.00
Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem (2008) 2.27
Anionic micelles and vesicles induce tau fibrillization in vitro. J Biol Chem (2003) 1.73
Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. J Biol Chem (2003) 1.62
New directions for frontotemporal dementia drug discovery. Alzheimers Dement (2007) 1.53
Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem (2005) 1.45
Nonhuman primate model of pertussis. Infect Immun (2012) 1.45
Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem (2008) 1.42
Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry (2005) 1.41
Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis (2010) 1.39
Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J Biol Chem (2004) 1.27
Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry (2004) 1.25
Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem (2007) 1.19
Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain. Infect Immun (2005) 1.17
Progranulin expression is upregulated after spinal contusion in mice. Acta Neuropathol (2009) 1.17
Chromatin condensation in terminally differentiating mouse erythroblasts does not involve special architectural proteins but depends on histone deacetylation. Chromosome Res (2009) 1.16
Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem (2004) 1.11
Tau isoform composition influences rate and extent of filament formation. J Biol Chem (2012) 1.11
Research towards tau imaging. J Alzheimers Dis (2011) 1.11
C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett (2005) 1.09
Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res Mol Brain Res (2005) 1.08
Electron microscopy as a quantitative method for investigating tau fibrillization. Anal Biochem (2004) 1.07
Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry (2005) 1.01
Evidence for an intermediate in tau filament formation. Biochemistry (2004) 1.01
Casein kinase-1 isoforms differentially associate with neurofibrillary and granulovacuolar degeneration lesions. Acta Neuropathol (2006) 1.00
Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain (2006) 1.00
Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis (2007) 1.00
A static laser light scattering assay for surfactant-induced tau fibrillization. Anal Biochem (2004) 0.99
Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech (2002) 0.98
Tau impacts on growth-factor-stimulated actin remodeling. J Cell Sci (2007) 0.98
Detection and quantification of tau aggregation using a membrane filter assay. Anal Biochem (2007) 0.97
Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Arch Biochem Biophys (2007) 0.97
Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem (2010) 0.96
Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. J Neurochem (2008) 0.96
Structure-activity relationship of cyanine tau aggregation inhibitors. J Med Chem (2009) 0.93
Site-specific pseudophosphorylation modulates the rate of tau filament dissociation. FEBS Lett (2005) 0.91
Inhibition of tau polymerization with a cyanine dye in two distinct model systems. J Biol Chem (2009) 0.90
Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical for nocodazole-induced mitotic arrest. Biochemistry (2006) 0.89
Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer's disease pathology. Int J Alzheimers Dis (2012) 0.88
Two distinct domains of protein 4.1 critical for assembly of functional nuclei in vitro. J Biol Chem (2002) 0.87
Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect (2007) 0.87
Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res (2004) 0.87
Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Abeta (25-35): involvement of lipid rafts. J Alzheimers Dis (2009) 0.87
Potent inhibition of tau fibrillization with a multivalent ligand. Biochem Biophys Res Commun (2007) 0.85
Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J Alzheimers Dis (2008) 0.84
Two protein 4.1 domains essential for mitotic spindle and aster microtubule dynamics and organization in vitro. J Biol Chem (2004) 0.84
Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol (2011) 0.84
Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett (2007) 0.84
Dysbindin structural homologue CK1BP is an isoform-selective binding partner of human casein kinase-1. Biochemistry (2006) 0.84
Ligand polarizability contributes to tau fibril binding affinity. Bioorg Med Chem (2011) 0.83
Small-molecule mediated neuroprotection in an in situ model of tauopathy. Neurotox Res (2009) 0.83
Microtubule-associated protein tau in human prostate cancer cells: isoforms, phosphorylation, and interactions. J Cell Biochem (2009) 0.83
Tau in MAPK activation. Front Neurol (2013) 0.83
Exonic point mutations of human tau enhance its toxicity and cause characteristic changes in neuronal morphology, tau distribution and tau phosphorylation in the lamprey cellular model of tauopathy. J Alzheimers Dis (2009) 0.82
Tau protein binds single-stranded DNA sequence specifically--the proof obtained in vitro with non-equilibrium capillary electrophoresis of equilibrium mixtures. FEBS Lett (2005) 0.82
QSAR studies for prediction of cross-β sheet aggregate binding affinity and selectivity. Bioorg Med Chem (2012) 0.80
Pseudophosphorylation of tau protein directly modulates its aggregation kinetics. Biochim Biophys Acta (2010) 0.79
Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: a simulation study. Neuroimage (2012) 0.79
Structural determinants of Tau aggregation inhibitor potency. J Biol Chem (2013) 0.79
Ligand electronic properties modulate tau filament binding site density. Biophys Chem (2012) 0.77
Structure-activity relationship of cyclic thiacarbocyanine tau aggregation inhibitors. Bioorg Med Chem Lett (2011) 0.77
Modulation and detection of tau aggregation with small-molecule ligands. Curr Alzheimer Res (2009) 0.77
Counselors' and consumers' derived criteria for assessing the effectiveness of rehabilitation services. Int J Rehabil Res (2003) 0.75
Transient expression of fluorescent tau proteins promotes process formation in PC12 cells: contributions of the tau C-terminus to this process. J Neurosci Res (2002) 0.75
Case series on aripiprazole and dopamine supersensitivity psychosis. Int Clin Psychopharmacol (2022) 0.75